Drugs / Pharmacological ascorbate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02905578 | Nov 2018 → Aug 2024 | adenocarcinoma, malignant pancreatic neoplasm | Joseph J. Cullen | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pharmacological ascorbate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02905578 ↗ |
| Route | Intravenous | “The ascorbate is administered intravenously - through a vein in the arm.” NCT02905578 ↗ |